[HTML][HTML] B-1 cell heterogeneity and the regulation of natural and antigen-induced IgM production
N Baumgarth - Frontiers in immunology, 2016 - frontiersin.org
A small subset of B cells, termed B-1 cells, with developmental origins, phenotypes, and
functions that are distinct from those of conventional B cells exist in mice. It contributes the …
functions that are distinct from those of conventional B cells exist in mice. It contributes the …
The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease
MB Fessler - Pharmacology & therapeutics, 2018 - Elsevier
Abstract The Liver X Receptors (LXRs) are oxysterol-activated transcription factors that
upregulate a suite of genes that together promote coordinated mobilization of excess …
upregulate a suite of genes that together promote coordinated mobilization of excess …
[HTML][HTML] Formononetin attenuates atherosclerosis via regulating interaction between KLF4 and SRA in apoE-/-mice
C Ma, R Xia, S Yang, L Liu, J Zhang, K Feng… - Theranostics, 2020 - ncbi.nlm.nih.gov
Background and Purpose: Atherosclerosis is an underlying cause of coronary heart disease.
Foam cell, a hallmark of atherosclerosis, is prominently derived from monocyte-differentiated …
Foam cell, a hallmark of atherosclerosis, is prominently derived from monocyte-differentiated …
Transcription factor 21 accelerates vascular calcification in mice by activating the IL-6/STAT3 signaling pathway and the interplay between VSMCs and ECs
X Zhao, M Zhu, S Wang, T Zhang, X Wei… - Acta Pharmacologica …, 2023 - nature.com
Vascular calcification is caused by the deposition of calcium salts in the intimal or tunica
media layer of the aorta, which increases the risk of cardiovascular events and all-cause …
media layer of the aorta, which increases the risk of cardiovascular events and all-cause …
[HTML][HTML] ERK1/2 inhibition reduces vascular calcification by activating miR-126-3p-DKK1/LRP6 pathway
P Zeng, J Yang, L Liu, X Yang, Z Yao, C Ma, H Zhu… - Theranostics, 2021 - ncbi.nlm.nih.gov
Rationale: Vascular microcalcification increases the risk of rupture of vulnerable
atherosclerotic lesions. Inhibition of ERK1/2 reduces atherosclerosis in animal models while …
atherosclerotic lesions. Inhibition of ERK1/2 reduces atherosclerosis in animal models while …
Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice
Objective—Activation of liver X receptor (LXR) inhibits atherosclerosis but induces
hypertriglyceridemia. In vitro, it has been shown that mitogen-activated protein kinase kinase …
hypertriglyceridemia. In vitro, it has been shown that mitogen-activated protein kinase kinase …
Phosphatidylserine liposomes mimic apoptotic cells to attenuate atherosclerosis by expanding polyreactive IgM producing B1a lymphocytes
H Hosseini, Y Li, P Kanellakis, C Tay… - Cardiovascular …, 2015 - academic.oup.com
Aims To investigate whether activation of atheroprotective peritoneal B1a cells by apoptotic
cells or phosphatidylserine liposomes (PSLs) can enhance their protective actions during …
cells or phosphatidylserine liposomes (PSLs) can enhance their protective actions during …
[HTML][HTML] 25-Hydroxycholesterol activates the expression of cholesterol 25-hydroxylase in an LXR-dependent mechanism [S]
Cholesterol 25-hydroxylase (CH25H) catalyzes the production of 25-hydroxycholesterol (25-
HC), an oxysterol that can play an important role in different biological processes. However …
HC), an oxysterol that can play an important role in different biological processes. However …
[HTML][HTML] The role of cytokines in cholesterol accumulation in cells and atherosclerosis progression
AM Markin, YV Markina, AI Bogatyreva… - International Journal of …, 2023 - mdpi.com
Atherosclerosis is the most common cardiovascular disease and is the number one cause of
death worldwide. Today, atherosclerosis is a multifactorial chronic inflammatory disease with …
death worldwide. Today, atherosclerosis is a multifactorial chronic inflammatory disease with …
A novel therapy for hepatic cholestasis treatment—the combination of rosiglitazone and fenofibrate
Hepatic cholestasis can develop into liver fibrosis and eventually liver failure. Currently,
ursodeoxycholic acid (UDCA) or UDCA combined with fenofibrate is used for cholestasis …
ursodeoxycholic acid (UDCA) or UDCA combined with fenofibrate is used for cholestasis …